Global Leading Market Research Publisher QYResearch announces the release of its latest report “C-Reactive Protein (CRP) Assay Kit – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. This comprehensive study delivers an authoritative analysis of the global C-reactive protein (CRP) assay kit market, integrating historical impact data (2021-2025) with forward-looking forecast calculations (2026-2032). Covering critical dimensions such as market size, market share, demand trajectories, industry development status, and long-term growth projections, this report serves as an essential strategic resource for stakeholders across clinical diagnostics, point-of-care testing, hospital laboratories, and immunoassay manufacturing sectors.
For clinical laboratory directors, infectious disease specialists, and primary care physicians confronting the fundamental challenge of rapidly assessing inflammation and infection status in patients—where timely diagnosis directly impacts treatment decisions and patient outcomes—C-reactive protein (CRP) assay kits represent the essential diagnostic tool that transforms acute-phase protein measurement from a specialized test to a routine clinical assessment. Traditional CRP testing requires centralized laboratory infrastructure, extended turnaround times, and specialized equipment that delays clinical decision-making. CRP assay kits address this gap through diverse technology platforms—including immunoturbidimetry for high-throughput laboratories, immunochromatography for point-of-care settings, and enzyme-linked immunoassays for research applications—enabling rapid, sensitive detection of CRP levels that support auxiliary diagnosis, therapeutic monitoring, and prognosis evaluation across infectious disease, inflammatory conditions, cardiovascular risk assessment, and post-surgical monitoring.
Market Growth Outlook: A US$199 Million Opportunity at 6.1% CAGR
The global C-reactive protein (CRP) assay kit market demonstrated strong growth fundamentals in 2025, with total market value estimated at US$ 132 million. According to QYResearch’s latest industry analysis, this figure is projected to expand to US$ 199 million by 2032, representing a steady compound annual growth rate (CAGR) of 6.1% over the forecast period. In volume terms, global production reached approximately 3.96 million units in 2024, with average unit pricing of US$ 31.50. This sustained growth trajectory reflects the expanding role of CRP testing in clinical practice, increasing prevalence of inflammatory conditions, and growing adoption of point-of-care diagnostics across healthcare settings.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096695/c-reactive-protein–crp–assay-kit
Product Definition: In Vitro Diagnostic Tools for Inflammation Assessment
A C-reactive protein (CRP) assay kit is an in vitro diagnostic product designed for the quantitative or qualitative determination of CRP levels in serum, plasma, or other biological samples. CRP is an acute-phase protein synthesized primarily by the liver in response to inflammatory stimuli; elevated concentrations are associated with inflammation, infection, tissue injury, and various pathological conditions. These assay kits are widely applied in clinical practice for auxiliary diagnosis, therapeutic monitoring, and prognosis evaluation across multiple medical specialties.
Core Technology Platforms:
Immunoturbidimetric Assay Kits:
Principle: Antibody-antigen complexes measured by light scattering or absorbance
Throughput: High-volume automated analyzers; 100–500 tests per hour
Applications: Centralized hospital laboratories; high-volume testing
Advantages: Automation; high throughput; quantitative results
Limitations: Requires specialized instrumentation; centralized setting
Immunochromatographic Assay Kits:
Principle: Lateral flow technology; visual or reader-based results
Throughput: Point-of-care; 1–10 tests per hour per operator
Applications: Emergency departments; physician offices; outpatient clinics
Advantages: Rapid (5–15 minutes); no instrumentation; portable
Limitations: Semi-quantitative or limited quantitative; lower throughput
Enzyme-linked Immunoassay (ELISA) Kits:
Principle: Enzyme-linked antibody detection with colorimetric readout
Throughput: Moderate; 96-well plate format; batch processing
Applications: Research laboratories; specialized clinical testing
Advantages: High sensitivity; quantitative; established methodology
Limitations: Longer turnaround (1–4 hours); laboratory setting
Key Performance Characteristics:
Detection range: 0.5–200 mg/L depending on kit configuration
Sensitivity: As low as 0.1 mg/L for high-sensitivity CRP (hs-CRP)
Specificity: Minimal cross-reactivity with other acute-phase proteins
Sample type: Serum, plasma, whole blood, or capillary blood
Turnaround time: 5–60 minutes depending on technology
Storage: 2–8°C refrigerated; room temperature stable options
Clinical Applications:
Infection and Inflammation:
Bacterial vs. viral differentiation: Elevated CRP suggests bacterial etiology
Sepsis monitoring: Serial CRP for treatment response
Post-operative monitoring: Infection detection after surgery
Autoimmune disease: Disease activity assessment
Cardiovascular Risk Assessment:
High-sensitivity CRP (hs-CRP): Cardiovascular risk stratification
Primary prevention: Risk assessment in asymptomatic patients
Secondary prevention: Monitoring in established cardiovascular disease
Guideline integration: Incorporated into risk assessment algorithms
Chronic Disease Management:
Rheumatoid arthritis: Disease activity monitoring
Inflammatory bowel disease: Flare detection and treatment response
Chronic kidney disease: Inflammation assessment
COPD: Exacerbation detection
Critical Care:
ICU monitoring: Serial CRP for infection detection
Trauma: Inflammation assessment after injury
Burn care: Infection monitoring
Market Drivers and Structural Trends
Expanding Clinical Utility:
CRP testing applications continue to expand across medical specialties:
Infectious disease: Differentiating bacterial from viral infections
Cardiovascular medicine: hs-CRP for risk assessment
Rheumatology: Disease activity monitoring
Surgery: Post-operative infection surveillance
Point-of-Care Testing Growth:
Decentralized testing drives market expansion:
Emergency departments: Rapid rule-out of infection
Primary care: Immediate results for antibiotic stewardship
Outpatient clinics: Same-visit diagnosis
Resource-limited settings: Instrument-free testing options
Aging Population:
Increasing prevalence of inflammatory conditions in aging populations:
Chronic inflammation: Age-related inflammatory conditions
Cardiovascular disease: Increasing risk assessment demand
Autoimmune disorders: Growing patient populations
Post-surgical monitoring: Increased surgical volume
Technological Advancement:
Assay technology continues to evolve:
High-sensitivity CRP: Expanded cardiovascular applications
Multiplex platforms: Combined testing with other biomarkers
Digital integration: Connectivity for data management
Automated systems: Improved workflow efficiency
Segment Analysis and Market Dynamics
Segment by Technology Type:
Immunoturbidimetric Assay Kits: Largest segment; high-volume laboratories; automated systems
Immunochromatographic Assay Kits: Fastest-growing segment; point-of-care applications; decentralized testing
Enzyme-linked Immunoassay Kits: Established segment; research applications; specialized testing
Segment by End User:
Hospital: Largest segment; centralized laboratories; inpatient and outpatient testing
Clinic: Growing segment; point-of-care testing; physician offices
Physical Examination Center: Expanding segment; wellness screening; preventive medicine
Other: Research laboratories; reference laboratories
Competitive Landscape: Key Manufacturers
The global C-reactive protein (CRP) assay kit market features established diagnostic companies with immunoassay expertise. Key manufacturers profiled in the report include:
Global Leaders:
Thermo Fisher Scientific
GenScript
Bio-Techne
Horiba
Dymin Biotech
Fujifilm
Abbott
Siemens
Orion Diagnostica
Asia-Pacific Leaders:
Maccura
Mindray
Huisong Technology
Zybio
Shandong Excellence Biotechnology
Jiangxi Tekang Technology
Strategic Outlook and Exclusive Market Insights
The Point-of-Care Paradigm Shift:
From an industry analyst’s perspective, the CRP assay kit market is experiencing a fundamental shift from centralized laboratory testing to decentralized point-of-care diagnostics. Immunochromatographic platforms enable CRP testing in settings where laboratory infrastructure is limited or turnaround time is critical—emergency departments, primary care offices, and resource-limited settings. This decentralization expands the addressable market and aligns with broader healthcare trends toward accessible, rapid diagnostics.
High-Sensitivity CRP Market Expansion:
hs-CRP testing for cardiovascular risk assessment represents a distinct market segment with different clinical applications and performance requirements:
Conventional CRP: 5–200 mg/L range; infection and inflammation
hs-CRP: 0.5–10 mg/L range; cardiovascular risk assessment
Clinical guidelines: Integrated into risk assessment algorithms
Population screening: Preventive medicine applications
Technology Platform Segmentation:
Different technology platforms serve distinct market segments:
Immunoturbidimetry: High-volume laboratories; automation; cost-per-test advantages
Immunochromatography: Point-of-care; convenience; rapid results
ELISA: Research; specialized applications; high sensitivity
Manufacturers offering multiple platforms capture broader market segments.
Geographic Market Dynamics:
North America: Largest market; high laboratory automation; strong point-of-care adoption
Europe: Advanced market; regulatory framework; established clinical guidelines
Asia-Pacific: Fastest-growing region; expanding healthcare infrastructure; increasing testing volumes; China, Japan, India as growth markets
Emerging Markets: Developing laboratory infrastructure; growing point-of-care adoption
Future Technology Trajectories:
The CRP assay kit market will be shaped by:
Multiplex platforms: Combined CRP with procalcitonin, IL-6, and other biomarkers
Digital integration: Connectivity for remote monitoring and data management
Extended shelf life: Room temperature stable formats
Quantitative POC: Enhanced quantification for point-of-care platforms
Non-invasive sampling: Saliva or other alternative sample types
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
